We use CRT (Cardiac Resynchronization Therapy) to treat dyssynchrony and heart failure. However, 30-40% of patients do not respond to the current method. For these patients may solution be a new wireless endocardial CRT pacing. Power is supplied wirelessly via a subcutaneous ultrasound pulse generator. WiSE-CRT therapy offers many advantages, including the ability to provide local stimulation and targeted stimulation without regard to the implantation site in the left ventricle. Other benefits that were noted during treatment include QRS shorter duration, an increase in ejection fraction, and no need for treatment with anticoagulants. In addition, patients do not suffer from endocarditis associated with conventionally CRT. The efficacy of WiSE-CRT is tested, as it has already been positively evaluated in Europe.